Thursday, August 10, 2017 7:10:06 AM
So the bare minimum stock price to uplist is $2 assuming other requirements are met. That equates to a $0.33/share pre reverse split price. That should be the floor. Realistically speaking, if they want to raise additional capital and attract institutional investors, they need the stock price to be above $5 (usually well above..how many IPOs have you seen done at $5?).
Regarding the $200mm in net asset comment (again that's market value, not book value, which is what determines the stock price), if you think they don't have that, where do you disagree with the analysis posted in the sticky notes section? Keep in mind that analysis excluded the potential value from the cannabis-based drug that they are pursuing. If you take the mid point of that valuation ($330mm), the stock price pre-split should be over $1.
The dilution was tough to take, and I think poorly timed and naive on their part, but those selling below $0.20 yesterday will regret it IMO. I think the stock should be selling at $0.50-$0.80 at a minimum, but we might have to wait until they file financials and disclose more information on their assets.
Recent NXEN News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 11:19:50 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/14/2024 11:04:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 08:02:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 08:02:23 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 10:06:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2023 09:41:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2023 07:35:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM